Skip to main content
Erschienen in: Medical Oncology 3/2013

01.09.2013 | Original Paper

Role of KAI1/CD82 polymorphisms in colon cancer risk in Han Chinese population

verfasst von: Zhen-Bin Ma, Kun Li, Jian Wang, Guang-Hong Guo

Erschienen in: Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to investigate the associations between KAI1/CD82 gene polymorphisms and colorectal cancer (CRC)-risk predisposition. We undertook a case–control study to analyze two KAI1/CD82 polymorphisms (exon 3 −29166 C>T and exon 9 −52840 C>A) in an Han Chinese population, by extraction of genomic DNA from the peripheral blood of 356 patients with CRC and 378 control participants, and performed KAI1/CD82 genotyping using DNA sequencing. The obtained results indicated that overall, no statistically significant association was observed in exon 9 (−52840 C>A). Nevertheless, exon 3 (−29166 C>T) genotype was at increased risk of CRC (P = 0.006; odds ratio = 1.299, CI 95 % 1.058–1.549). Furthermore, −29166 T allele CRCs were more significantly common in patients with tumor size of >4 cm than C allele CRC and in cases of poor differentiation and advanced pathological stage. These findings led us to conclude that polymorphism in exon 3 (−29166 C>T) was observed to be associated with susceptibility of CRC. However, exon 9 (−52840 C>A) polymorphism showed no correlation to CRC susceptibility. Nevertheless, further investigation with a larger sample size is needed to support our results.
Literatur
2.
Zurück zum Zitat Zhu QC, Jin ZM. Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer. Zhonghua Zhong Liu Za Zhi. 2011;33(5):388–90.PubMed Zhu QC, Jin ZM. Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer. Zhonghua Zhong Liu Za Zhi. 2011;33(5):388–90.PubMed
4.
Zurück zum Zitat Moreaux J, Catala M. Carcinoma of the colon: long-term survival and prognosis after surgical treatment in a series of 798 patients. World J Surg. 1987;11(6):804–9.PubMedCrossRef Moreaux J, Catala M. Carcinoma of the colon: long-term survival and prognosis after surgical treatment in a series of 798 patients. World J Surg. 1987;11(6):804–9.PubMedCrossRef
5.
Zurück zum Zitat Burt RW. Strategies for colon cancer screening with considerations of cost and access to care. J Natl Compr Canc Netw. 2010;8(1):2–5.PubMed Burt RW. Strategies for colon cancer screening with considerations of cost and access to care. J Natl Compr Canc Netw. 2010;8(1):2–5.PubMed
7.
Zurück zum Zitat Zhang L, Zhang G, Wang P, Gong J, Cao Y, Tang L. Association of vascular endothelial growth factor −2578C/A gene polymorphism in Chinese patients with colon cancer. Genet Test Mol Biomarkers. 2011;15(3):117–21. doi:10.1089/gtmb.2010.0166.PubMedCrossRef Zhang L, Zhang G, Wang P, Gong J, Cao Y, Tang L. Association of vascular endothelial growth factor −2578C/A gene polymorphism in Chinese patients with colon cancer. Genet Test Mol Biomarkers. 2011;15(3):117–21. doi:10.​1089/​gtmb.​2010.​0166.PubMedCrossRef
10.
Zurück zum Zitat Mannion BA, Berditchevski F, Kraeft SK, Chen LB, Hemler ME. Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associated with integrin alpha 4 beta 1 (CD49d/CD29). J Immunol. 1996;157(5):2039–47.PubMed Mannion BA, Berditchevski F, Kraeft SK, Chen LB, Hemler ME. Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associated with integrin alpha 4 beta 1 (CD49d/CD29). J Immunol. 1996;157(5):2039–47.PubMed
11.
Zurück zum Zitat Hemler ME, Mannion BA, Berditchevski F. Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta. 1996;1287(2–3):67–71.PubMed Hemler ME, Mannion BA, Berditchevski F. Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta. 1996;1287(2–3):67–71.PubMed
14.
Zurück zum Zitat Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res. 1996;56(19):4387–90.PubMed Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res. 1996;56(19):4387–90.PubMed
15.
Zurück zum Zitat Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 1995;268(5212):884–6.PubMedCrossRef Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 1995;268(5212):884–6.PubMedCrossRef
17.
Zurück zum Zitat Yu Y, Yang JL, Markovic B, Jackson P, Yardley G, Barrett J, et al. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clin Cancer Res. 1997;3(7):1045–9.PubMed Yu Y, Yang JL, Markovic B, Jackson P, Yardley G, Barrett J, et al. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clin Cancer Res. 1997;3(7):1045–9.PubMed
18.
20.
Zurück zum Zitat Hinoda Y, Adachi Y, Takaoka A, Mitsuuchi H, Satoh Y, Itoh F, et al. Decreased expression of the metastasis suppressor gene KAI1 in gastric cancer. Cancer Lett. 1998;129(2):229–34. doi:S0304-3835(98)00112-8.PubMedCrossRef Hinoda Y, Adachi Y, Takaoka A, Mitsuuchi H, Satoh Y, Itoh F, et al. Decreased expression of the metastasis suppressor gene KAI1 in gastric cancer. Cancer Lett. 1998;129(2):229–34. doi:S0304-3835(98)00112-8.PubMedCrossRef
21.
Zurück zum Zitat Uchida S, Shimada Y, Watanabe G, Li ZG, Hong T, Miyake M, et al. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer. 1999;79(7–8):1168–73. doi:10.1038/sj.bjc.6690186.PubMedCrossRef Uchida S, Shimada Y, Watanabe G, Li ZG, Hong T, Miyake M, et al. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer. 1999;79(7–8):1168–73. doi:10.​1038/​sj.​bjc.​6690186.PubMedCrossRef
23.
Zurück zum Zitat Nazir M, Kayani MR, Malik FA, Masood N, Kayani MA. Lack of germ line changes in KISS1 and KAI1 genes in sporadic head and neck cancer patients of Pakistani origin. Asian Pac J Cancer Prev. 2011;12(10):2767–71.PubMed Nazir M, Kayani MR, Malik FA, Masood N, Kayani MA. Lack of germ line changes in KISS1 and KAI1 genes in sporadic head and neck cancer patients of Pakistani origin. Asian Pac J Cancer Prev. 2011;12(10):2767–71.PubMed
24.
Zurück zum Zitat Boland CR. Molecular genetics of hereditary nonpolyposis colorectal cancer. Ann N Y Acad Sci. 2000;910:50–9; discussion 9–61. Boland CR. Molecular genetics of hereditary nonpolyposis colorectal cancer. Ann N Y Acad Sci. 2000;910:50–9; discussion 9–61.
25.
Zurück zum Zitat Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
26.
Zurück zum Zitat Miyake M, Hakomori SI. A specific cell surface glycoconjugate controlling cell motility: evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochemistry. 1991;30(13):3328–34.PubMedCrossRef Miyake M, Hakomori SI. A specific cell surface glycoconjugate controlling cell motility: evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochemistry. 1991;30(13):3328–34.PubMedCrossRef
27.
Zurück zum Zitat Hashida H, Takabayashi A, Adachi M, Imai T, Kondo K, Kohno N, et al. The novel monoclonal antibody MH8-4 inhibiting cell motility recognizes integrin alpha 3: inverse of its expression withmetastases in colon cancer. Int J Oncol. 2001;18(1):89–95.PubMed Hashida H, Takabayashi A, Adachi M, Imai T, Kondo K, Kohno N, et al. The novel monoclonal antibody MH8-4 inhibiting cell motility recognizes integrin alpha 3: inverse of its expression withmetastases in colon cancer. Int J Oncol. 2001;18(1):89–95.PubMed
28.
Zurück zum Zitat Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology. 2002;122(2):376–86. doi:S0016508502084482.PubMedCrossRef Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology. 2002;122(2):376–86. doi:S001650850208448​2.PubMedCrossRef
29.
Zurück zum Zitat Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol. 1999;146(2):389–403.PubMedCrossRef Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol. 1999;146(2):389–403.PubMedCrossRef
33.
Zurück zum Zitat Uzawa K, Ono K, Suzuki H, Tanaka C, Yakushiji T, Yamamoto N, et al. High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis. Clin Cancer Res. 2002;8(3):828–35.PubMed Uzawa K, Ono K, Suzuki H, Tanaka C, Yakushiji T, Yamamoto N, et al. High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis. Clin Cancer Res. 2002;8(3):828–35.PubMed
Metadaten
Titel
Role of KAI1/CD82 polymorphisms in colon cancer risk in Han Chinese population
verfasst von
Zhen-Bin Ma
Kun Li
Jian Wang
Guang-Hong Guo
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0668-7

Weitere Artikel der Ausgabe 3/2013

Medical Oncology 3/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.